Articles Accepted

COMPARISON OF ACID DEGRADANT PRODUCT WITH METABOLIC PATHWAY OF REMOGLIFLOZIN ETABONATE IN DEVELOPED AND VALIDATED RP-HPTLC METHOD
by Dr. Dr. Akhil Nagar, 13 Sep 2021
Co-Author(s): samadhan shinde,Ruchita Bardiya,Pritam Jain,Atul Shirkhedkar

Force degradation studies in tablet and bulk formulations of Remogliflozin etabonate have been developed using a precise and sensitive high performance thin layer chromatographic method. The silica gel RP-18 F254S plates were used as the stationary phase and ACN: Water: Ammonia solution (8:2:0.5 V/V/V) was used as the mobile phase for estimation. The proposed method was successfully validated, showing the Rf of the drug as 0.72 at 229 nm. The method was observed to be linear in the range of 500-3000 ng/band and then degradation was estimated by force degradation pathway. In the force degradation studies, the drug was found to be highly susceptible to both acid and base, including oxidative conditions, providing an active metabolite when remaining in contact in stressed conditions for a short time (30 min), while in longer duration (36 hr), the drug provided another metabolite which on characterization was found to be inactive and predicted to be reported in the metabolic pathway.

Current Issue
August 2022
Quick Contact